Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02879097

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:07.701516+00:00

Published At

2016-08-25T00:00:00+00:00

Record Updated At

2016-08-25

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-Small Cell Lung Carcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2016-08-25"

protocolSection.identificationModule.nctId

"NCT02879097"

protocolSection.identificationModule.officialTitle

"Efficacy, Safety \u0026 Immunogenicity Study of CBT124 \u0026 EU-sourced Avastin\u00ae in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Non-Small Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.